jili tutorial

GLP-1 Drugs: A Potential Game-Changer for Problem Gambling?

By jili tutorial · October 12, 2026

GLP-1 Drugs: A Potential Game-Changer for Problem Gambling?

Introduction to GLP-1 Medications

Originally developed to manage blood sugar levels in individuals with type 2 diabetes, GLP-1 (Glucagon-Like Peptide-1) drugs have since expanded their reach into various medical conditions. Medications like Ozempic, Wegovy, and Rybelsus, which contain the active ingredient semaglutide, are now widely used for treating obesity, liver disease, and kidney disease. Recent research suggests that these drugs may also have a significant impact on behavioral addictions, including problem gambling.

The Science Behind GLP-1 and Reward Systems

How GLP-1 Drugs Work

GLP-1 drugs function by mimicking the action of the GLP-1 hormone, which enhances insulin secretion, suppresses appetite, and slows gastric emptying. Beyond these metabolic effects, emerging evidence indicates that GLP-1 medications influence the brain’s reward processes, potentially reducing cravings for certain behaviors.

The Role of Dopamine

The brain’s reward system involves neurotransmitters like dopamine, which is associated with feelings of pleasure and reinforcement. Activities such as gambling, drinking, or shopping trigger dopamine release, creating a cycle of craving and reward. GLP-1 drugs appear to “turn down” these reward signals, making them less intense and reducing the urge to engage in compulsive behaviors.

Research Findings

In May 2023, Boston University researchers highlighted the potential of GLP-1 drugs to curb not just food cravings but also cravings for alcohol, shopping, and gambling. Dr. Ivania Rizo, an assistant professor of medicine, noted that these medications could fundamentally alter how the brain processes rewards.

Expanding the Scope: Financial Decision-Making

Wharton School’s Investigation

Researchers at the University of Pennsylvania’s Wharton School are taking this idea a step further by exploring how GLP-1 drugs might influence financial decision-making. Neuroscientist Michael Platt suggests that these medications could lead to structural remodeling of the brain, affecting long-term choices related to food and finances.

MindCORE Study

The university’s MindCORE (Mind Center for Outreach, Research, and Education) is launching a study involving 180 participants to better understand the effects of GLP-1 drugs on financial behavior. Participants will undergo regular MRI scans to monitor brain activity associated with risk and reward. Images of high-risk financial activities, such as casinos or lottery jackpots, will be used to stimulate dopamine responses.

Potential Implications

Michael Platt speculates that dampening reward signals could reduce the appetite for high-risk financial ventures among professionals while helping everyday consumers resist impulsive spending. This dual effect could lead to more prudent financial behavior across different demographics.

The Growing Gambling Epidemic

Current Statistics

The National Council on Problem Gambling (NCPG) estimates that approximately 20 million U.S. adults struggle with gambling addiction. This number is on the rise, driven by the increasing prevalence of gambling in society. In 2025, commercial and tribal casinos generated a record-breaking $125 billion in gross gaming revenue, excluding losses from lotteries, prediction markets, and unlicensed online gambling.

A 2026 study by Northwestern Mutual revealed that younger generations are particularly susceptible to high-risk financial activities like sports betting and prediction market trading. Gen Z leads the pack at 32%, followed by Millennials at 24%. In contrast, only 3% of Baby Boomers engage in these activities.

Funding and Support

Digital Health Company Noom

The Penn study is funded by Noom, a digital health company known for its weight-loss programs. Noom’s involvement underscores the broader potential of GLP-1 drugs beyond their initial medical applications.

Practical Implications and Future Directions

For Problem Gamblers

If GLP-1 drugs prove effective in curbing gambling cravings, they could become a valuable tool in addiction treatment. This would complement existing therapies like cognitive-behavioral therapy (CBT) and support groups.

For Financial Decision-Making

The potential impact on financial behavior could extend beyond individuals with gambling disorders. By reducing impulse-driven decisions, GLP-1 drugs might help people achieve long-term financial goals, such as saving for retirement or avoiding debt.

Conclusion

GLP-1 drugs, initially designed for diabetes and weight management, are emerging as a promising intervention for behavioral addictions like problem gambling. As research continues to uncover their broader effects on the brain’s reward system, these medications could revolutionize how we approach addiction treatment and financial decision-making. However, further studies are needed to validate these findings and explore their practical applications.